(JANX) Janux Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 842m USD | Total Return: -42.4% in 12m

Immunotherapies, Cancer Therapeutics, Biopharmaceuticals, T-Cell Engagers
Total Rating 14
Safety 30
Buy Signal -0.06
Biotechnology
Industry Rotation: -8.2
Market Cap: 842M
Avg Turnover: 12.3M
Risk 3d forecast
Volatility75.0%
VaR 5th Pctl11.2%
VaR vs Median-11.4%
Reward TTM
Sharpe Ratio-0.30
Rel. Str. IBD6.4
Rel. Str. Peer Group4.8
Character TTM
Beta1.042
Beta Downside1.085
Hurst Exponent0.478
Drawdowns 3y
Max DD81.78%
CAGR/Max DD0.10
CAGR/Mean DD0.19
EPS (Earnings per Share) EPS (Earnings per Share) of JANX over the last years for every Quarter: "2021-03": -2.02, "2021-06": -0.62, "2021-09": -0.26, "2021-12": -0.33, "2022-03": -0.32, "2022-06": -0.41, "2022-09": -0.4, "2022-12": -0.39, "2023-03": -0.42, "2023-06": -0.42, "2023-09": -0.25, "2023-12": -0.25, "2024-03": -0.3, "2024-06": -0.11, "2024-09": -0.51, "2024-12": -0.36, "2025-03": -0.38, "2025-06": -0.55, "2025-09": -0.39, "2025-12": -0.51, "2026-03": -0.39,
Last SUE: 0.90
Qual. Beats: 3
Revenue Revenue of JANX over the last years for every Quarter: 2021-03: 0.38, 2021-06: 0.482, 2021-09: 1.159, 2021-12: 1.616, 2022-03: 1.589, 2022-06: 2.365, 2022-09: 1.813, 2022-12: 2.845, 2023-03: 2.048, 2023-06: 1.057, 2023-09: 2.517, 2023-12: 2.461, 2024-03: 1.252, 2024-06: 8.897, 2024-09: 0.439, 2024-12: -8.512, 2025-03: 0, 2025-06: 0, 2025-09: 10, 2025-12: 7.88, 2026-03: 3.733,
Rev. CAGR: 11.23%
Rev. Trend: 74.8%
Last SUE: -0.25
Qual. Beats: 0

Warnings

High Debt while negative Cash Flow

Beneish M-Score 1.00 > -1.5 - likely earnings manipulation

Altman Z'' -0.59 < 1.0 - financial distress zone

Tailwinds

Confidence

Description: JANX Janux Therapeutics

Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies for cancer and autoimmune diseases. The firm utilizes its proprietary TRACTr, TRACIr, and ARM platforms to engineer therapies designed to activate the immune system specifically within the tumor microenvironment, aiming to reduce systemic toxicity. This localized activation strategy addresses a primary challenge in the biotechnology sector, where off-target effects often limit the efficacy of T-cell engaging therapies.

The company’s lead clinical candidates, JANX007 and JANX008, are currently in Phase 1 trials targeting metastatic castration-resistant prostate cancer and various solid tumors, including colorectal and lung cancers. Janux also develops JANX011 for autoimmune conditions and maintains strategic research collaborations with Merck and Bristol Myers Squibb. For a more comprehensive look at these clinical milestones and partnership structures, consider reviewing the detailed reports on ValueRay. Founded in 2017 and headquartered in San Diego, Janux operates within the high-risk, high-reward drug development model typical of the clinical-stage biotech industry.

Headlines to Watch Out For
  • JANX007 clinical data readouts drive volatility in prostate cancer treatment prospects
  • Strategic collaboration milestones with Merck and Bristol Myers Squibb trigger cash infusions
  • FDA regulatory progress for TRACTr platform candidates dictates long-term valuation shifts
  • R&D expenditure levels for Phase 1 trials impact cash runway sustainability
  • Expansion into autoimmune markets with JANX011 diversifies the clinical pipeline risk profile
Piotroski VR-10 (Strict) 1.0
Net Income: -114.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.08 > 0.02 and ΔFCF/TA -3.21 > 1.0
NWC/Revenue: 4.36k% < 20% (prev 122k%; Δ -118k% < -1%)
CFO/TA -0.08 > 3% & CFO -77.5m > Net Income -114.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 17.01 > 1.5 & < 3
Outstanding Shares: last quarter (62.7m) vs 12m ago 1.41% < -2%
Gross Margin: 51.64% > 18% (prev -1.48%; Δ 5.31k% > 0.5%)
Asset Turnover: 2.08% > 50% (prev 0.08%; Δ 2.00% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -0.59
A: 0.92 (Total Current Assets 1.00b - Total Current Liabilities 58.9m) / Total Assets 1.03b
B: -0.37 (Retained Earnings -375.7m / Total Assets 1.03b)
C: -0.13 (EBIT TTM -135.6m / Avg Total Assets 1.04b)
D: -4.33 (Book Value of Equity -375.1m / Total Liabilities 86.7m)
Altman-Z'' = -0.59 = B
Beneish M 1.00
DSRI: 0.29 (Receivables 42.5m/5.58m, Revenue 21.6m/824k)
GMI: 1.00 (fallback, negative margins)
AQI: 1.35 (AQ_t 0.00 / AQ_t-1 0.00)
SGI: 26.23 (Revenue 21.6m / 824k)
TATA: -0.04 (NI -114.5m - CFO -77.5m) / TA 1.03b)
Beneish M = 14.65 (Cap -4..+1) = D
What is the price of JANX shares?

As of May 24, 2026, the stock is trading at USD 14.41 with a total of 613,526 shares traded.
Over the past week, the price has changed by +4.54%, over one month by -5.65%, over three months by +8.60% and over the past year by -42.40%.

Is JANX a buy, sell or hold?

Janux Therapeutics has received a consensus analysts rating of 4.77. Therefore, it is recommended to buy JANX.

  • StrongBuy: 11
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the JANX price?
Analysts Target Price 40.6 181.5%
Janux Therapeutics (JANX) - Fundamental Data Overview as of 21 May 2026
P/S = 61.3263
P/B = 0.8951
Revenue TTM = 21.6m USD
EBIT TTM = -135.6m USD
EBITDA TTM = -133.6m USD
Long Term Debt = 19.1m USD (estimated: total debt 21.6m - short term 2.47m)
Short Term Debt = 2.47m USD (from shortTermDebt, last quarter)
Debt = 21.6m USD (from shortLongTermDebtTotal, last quarter) (leases 21.6m already included)
Net Debt = -934.8m USD (calculated: Debt 21.6m - CCE 956.4m)
Enterprise Value = 842.2m USD (floored to Market Cap, CCE > MCap+Debt)
 Interest Coverage Ratio = unknown (Ebit TTM -135.6m / Interest Expense TTM 0.0)
 EV/FCF = -10.73x (Enterprise Value 842.2m / FCF TTM -78.5m)
FCF Yield = -9.32% (FCF TTM -78.5m / Enterprise Value 842.2m)
 FCF Margin = -363.2% (FCF TTM -78.5m / Revenue TTM 21.6m)
 Net Margin = -529.7% (Net Income TTM -114.5m / Revenue TTM 21.6m)
 Gross Margin = 51.64% ((Revenue TTM 21.6m - Cost of Revenue TTM 10.5m) / Revenue TTM)
Gross Margin QoQ = 87.44% (prev -13.45%)
Tobins Q-Ratio = 0.82 (Enterprise Value 842.2m / Total Assets 1.03b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 21.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -107.1m (EBIT -135.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.01 (Total Current Assets 1.00b / Total Current Liabilities 58.9m)
Debt / Equity = 0.02 (Debt 21.6m / totalStockholderEquity, last quarter 941.5m)
 Debt / EBITDA = 7.00 (negative EBITDA) (Net Debt -934.8m / EBITDA -133.6m)
 Debt / FCF = 11.91 (negative FCF - burning cash) (Net Debt -934.8m / FCF TTM -78.5m)
 Total Stockholder Equity = 966.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.01% (Net Income -114.5m / Total Assets 1.03b)
RoE = -8.53% (Net Income TTM -114.5m / Total Stockholder Equity 1.34b)
RoCE = -9.96% (EBIT -135.6m / Capital Employed (Equity 1.34b + L.T.Debt 19.1m))
 RoIC = -11.79% (negative operating profit) (NOPAT -107.1m / Invested Capital 908.6m)
 WACC = 9.41% (E(842.2m)/V(863.8m) * Re(9.65%) + D(21.6m)/V(863.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 13.98%
 [DCF] Fair Price = unknown (Cash Flow -78.5m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.90 | # QB: 3
Revenue Correlation: 74.80 | Revenue CAGR: 11.23% | SUE: -0.25 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.32 | Chg30d=+45.12% | Revisions=+0% | Analysts=13
EPS next Quarter (2026-09-30): EPS=-0.52 | Chg30d=+24.45% | Revisions=+20% | Analysts=13
EPS current Year (2026-12-31): EPS=-1.79 | Chg30d=+28.94% | Revisions=+69% | GrowthEPS=+2.2% | GrowthRev=+210.4%
EPS next Year (2027-12-31): EPS=-2.77 | Chg30d=+20.43% | Revisions=+73% | GrowthEPS=-55.0% | GrowthRev=-77.6%
[Analyst] Revisions Ratio: +73%